• Fosun unit Henlius won China NMPA clearance for pertuzumab biosimilar HANBEIYOU for HER2-positive early-stage, adjuvant, neoadjuvant, metastatic breast cancer.
• The product now holds regulatory authorizations in China, the US, the EU; US label includes interchangeability with Roche’s Perjeta.
• Henlius’ HANQUYOU trastuzumab with HANBEIYOU becomes the first China-developed trastuzumab-pertuzumab combination cleared in China, the US, the EU.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fosun International Limited published the original content used to generate this news brief on May 29, 2026, and is solely responsible for the information contained therein.